Академический Документы
Профессиональный Документы
Культура Документы
Abstract
Background: The purpose of this study is to report the efficacy of azithromycin 1.5% eye drops in children
with ocular rosacea and phlyctenular blepharokeratoconjunctivitis. This retrospective study from January 2009 to
March 2010 included 16 children treated with lid hygiene plus azithromycin 1.5% eye drops (AzyterW): 3-day
treatments (1 drop twice a day) every 10 days, reduced based on efficacy to one treatment every 15 days and
then to one treatment per month.
Results: Nineteen eyes of six boys and ten girls, aged 4 to 16 years (mean, 9.3 ± 4.0) were included. The disease was
previously resistant to lid hygiene (all the patients), oral erythromycin (one patient), and intermittent topical steroids
(six patients). The median duration of each phase of azithromycin treatment (i.e., three, two, and one treatments per
month) was 2 months. Ocular inflammation was controlled by azithromycin alone in 15 patients. In one uncontrolled
case, cyclosporine 2% eye drops was added at month 5. Bulbar conjunctival hyperemia resolved completely within
1 month in all eyes, whereas conjunctival phlyctenules and corneal inflammation took longer to improve, with a
complete resolution within 3 to 10 months. Blepharitis grade decreased from 2.31 ± 0.79 to 1.50 ± 0.73. Treatment
was stopped after a median of 6 months (from 4 to 10 months) without recurrence of corneoconjunctival
inflammation (median follow-up without treatment, 11 months). Six cases of ocular irritation were reported, two of
which led to treatment withdrawal.
Conclusion: Azithromycin 1.5% eye drops is an effective treatment for phlyctenular keratoconjunctivitis complicating
childhood ocular rosacea.
Keywords: Rosacea, Children, Keratoconjunctivitis, Blepharitis, Azithromycin
steroids or cyclosporine. Daily lid hygiene is the corner- Table 1 Patient demographics and baseline characteristics
stone of ocular rosacea treatment, with oral antibiotics Patient no. Sex Age Unilateral Evolution Treatment
required in case of lid hygiene failure or in severe forms (months)
of the disease. Second-generation tetracyclines are used 1 F 10 Yes 96 LH
in children over 8 years old, and erythromycin, 2 M 12 No 30 LH
azithromycin, or metronidazole are used in younger 3 F 7 Yes 15 LH + steroids
patients [6-8]. Topical antibiotics are often used, but
4 F 10 Yes 8 LH + steroids
very few publications support their efficacy [3]. Topical
5 F 7 Yes 15 LH
steroids are very effective but should only be used in
case of acute corneal inflammation due to the risk of 6 F 8 No 69 LH
iatrogenic complications. Cyclosporine 0.5% to 2% eye 7 M 15 Yes 18 LH + steroids
drops is an interesting alternative in children with 8 F 14 Yes 20 LH
steroid-dependent disease [9]. 9 F 6 Yes 10 LH + ERY
Azithromycin is a macrolide antibiotic characterized
10 F 16 No 90 LH
by a broad antibacterial spectrum, a long half-life related
11 M 5 Yes 12 LH + steroids
to its tissue and cell penetration [10], and anti-
inflammatory properties [11]. Oral azithromycin is an ef- 12 F 10 Yes 15 LH
fective treatment in ocular rosacea [12] and also in cuta- 13 M 5 Yes 27 LH + steroids
neous involvement of rosacea (with efficacy comparable 14 F 7 Yes 24 LH + steroids
to doxycycline) [13]. 15 M 4 Yes 20 LH
In this retrospective study, we assessed the efficacy of
16 M 15 Yes 148 LH
topical 1.5% azithromycin eye drops in children with ocular
LH, lid hygiene; ERY, oral erythromycin.
rosacea and phlyctenular blepharokeratoconjunctivitis.
Results
Sixteen children (19 eyes) were treated: six boys and ten treatment per month for a mean of 2 months (range, 0 to
girls with a mean age at initiation of azithromycin treat- 2 months). The disease was controlled by topical
ment of 9.3 ± 4.0 years (range, 4 to 16 years). azithromycin alone in 15 out of 16 patients (18 eyes).
The remaining patient (one eye) required the addition of
Childhood ocular rosacea status before azithromycin cyclosporine 2% eye drops for 5 months after 5 months
treatment of azithromycin in order to control ocular inflammation.
Pretreatment status is detailed for individual patients in Topical azithromycin dramatically improved ocular red-
Table 1. The disease was asymmetric or unilateral in 13 ness (reported by the patient) and bulbar conjunctival
children. Mean interval between onset of the disease and hyperemia (assessed by the ophthalmologist), both of
azithromycin treatment was 39 months (from 8 months which resolved within 1 month in all eyes (Figure 1A).
to 12 years). Two children had ongoing recurrent Conjunctival phlyctenules and corneal inflammation took
chalazia, whereas recurrent episodes of red eye were longer to improve, with a complete resolution within 3 to
reported in all cases. Bulbar conjunctival hyperemia and 10 months (Figure 1B,C). Inferior superficial punctate
phlyctenules were present in all eyes, and corneal in- keratitis only partially resolved in all eyes.
flammation was noted in all eyes but one. Therapy be- Blepharitis grading was available in 13 patients (16 eyes).
fore azithromycin (which had not controlled the Mean grade decreased from 2.31 ± 0.79 at baseline to 1.50
inflammation) consisted of lid hygiene in all cases plus ± 0.73 at the end of the treatment. Although anterior and
oral erythromycin in one case and intermittent topical posterior signs of blepharitis were not graded separately,
corticosteroids in six cases. Topical steroids and oral anterior blepharitis seemed to improve more significantly
erythromycin were stopped in all cases. than posterior blepharitis and meibomian gland dysfunc-
tion. However, no episodes of chalazion were noted during
Efficacy of azithromycin azithromycin treatment, even in the two children who
The treatment and follow-up durations per patient are complained of recurrent chalazia at baseline.
reported in Table 2. Topical azithromycin was adminis- Azithromycin was stopped when conjunctival phlycte-
tered for a mean of 6.0 ± 1.4 months (range, 4 to 10 nules and corneal inflammation had completely resolved,
months). Patients received three treatments of azithro- which occurred after a mean of 6.0 ± 1.4 months (between
mycin per month for a mean duration of 2 months 4 and 10 months). Corneoconjunctival inflammation did
(range, 1 to 6 months), then two treatments per month not recur with lid hygiene alone after a mean follow-up of
for a mean of 2 months (range, 1 to 2 months), then one 11.0 ± 1.7 months (8 to 14 months).
Doan et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:38 Page 3 of 6
http://www.joii-journal.com/content/3/1/38
withdrawn in all patients when topical azithromycin was replace oral antibiotics in this disease, but further con-
prescribed, and none of the patients required additional trolled studies are required.
steroid therapy thereafter.
In a previous study, we showed that topical 2% cyclo-
sporine is a very potent treatment of phlyctenular Methods
Design
blepharokeratoconjunctivitis [9]. The efficacy of topical
azithromycin was sufficient in most cases, but as clinical This is a retrospective, non-comparative, interventional
experience indicates that topical cyclosporine may have case series.
greater efficacy, patients with very severe corneal inflam-
mation were prescribed topical cyclosporine as first-line Methods
treatment. We reviewed the files of all 16 consecutive children with
A biphasic effect was observed in this study. The ef- rosacea and phlyctenular blepharokeratoconjunctivitis who
fect on ocular redness was very fast, within a month, were treated with topical 1.5% azithromycin eye drops be-
whereas phlyctenules and corneal infiltrates took sev- tween January 2009 and March 2010 in the Department of
eral months to heal. This may point to different Ophthalmology at Bichat Hospital and Fondation A. de
mechanisms. Ocular redness might be related to bac- Rothschild, Paris, France. Written informed consent was
terial toxin production. Phlyctenules and corneal obtained from the patients and from their parents for pub-
infiltrates are thought to be caused by a type IV cell- lication of this report. This study was approved by the Eth-
mediated delayed hypersensitivity reaction against parietal ics Committee of Foundation A de Rothschild.
staphylococcal antigens [5]. In addition to its antibiotic ef-
fect, azithromycin also has anti-inflammatory effects.
Indeed, it has been shown to reduce the production Treatment strategy
of the pro-inflammatory cytokines IL-12 and IL-6 by Patients presenting with ocular rosacea were initially
macrophages in vitro [11]; to suppress matrix treated with lid hygiene once daily, and frequent normal
metalloproteases 2 and 9, nuclear transcription factor saline instillations were initially prescribed alone for at
NFkB, and Toll-like receptor 2 in corneal epithelial least 1 month. Patients with sight-threatening corneal
cells in vitro [19,20]; and to inhibit macrophage and infiltrates approaching the visual axis were treated with
dendritic cell migration after corneal burn in a steroids and cyclosporine 2% eye drops and were not
mouse model [21]. treated with azithromycin; therefore, they were not
The safety profile of topical 1.5% azithromycin seems included in the study.
good in children suffering from ocular rosacea. Discon- Azithromycin 1.5% eye drops (AzyterW, Thea Laborator-
tinuous treatment with topical 1.5% azithromycin was ies) was administered only to patients who did not respond
well tolerated. Local intolerance was seen in a small to lid hygiene. A three-day treatment (1 drop bid) was ini-
number of cases and was usually mild, except in two tially prescribed every 10 days (i.e., three treatments
patients who stopped the treatment after 5 and 10 months, monthly) for at least 1 month. According to clinical effi-
respectively. Comparable side effects have been reported in cacy, treatment was tapered to one treatment every 15 days
the literature [17,18]. and then one treatment monthly.
The main limitation of our study is the small number
of patients, but rosacea in children is infrequent, and the Follow-up
largest series published to date included 44 children [3]. Patients were examined after 1 month and every 1 to 2
The retrospective nature of this study is also an im- months thereafter.
portant limitation. A multicenter prospective con- The main outcome measures were ocular redness
trolled study should be the next step for evaluating (reported by the patients), occurrence of chalazia (reported
azithromycin eyedrops in childhood ocular rosacea. by the patients), conjunctival bulbar hyperemia, conjunc-
tival phlyctenules, corneal inflammation (phlyctenules and
Conclusion infiltrates) and epitheliopathy, and lid margin inflammation
In conclusion, this retrospective study showed that top- (blepharitis). All measures were graded on scales of 0 to 4.
ical 1.5% azithromycin eye drops is an effective and safe Ocular rosacea was considered to be controlled if all items
treatment in non-severe forms of childhood ocular ros- except lid margin inflammation had a score of 0. Ocular
acea with phlyctenular blepharokeratoconjunctivitis. and systemic adverse events were also reported.
When treated under a discontinuous but prolonged regi-
men for at least 4 months, recurrences did not occur up
Competing interest
to 14 months after the end of treatment. Considering SD, FC, and IC are consultants for Thea Laboratories. However, they did not
the benefits/risk ratio, this new treatment could probably receive any financial support for this study.
Doan et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:38 Page 6 of 6
http://www.joii-journal.com/content/3/1/38